Cytokinetics (CYTK) insider Robert Blum reports 5,000-share sale

Rhea-AI Filing Summary

Robert I. Blum, President & CEO and a director of Cytokinetics, Inc. (CYTK), reported a sale of 5,000 shares of the issuer's common stock on 09/02/2025 at a reported price of $48.76 per share. After the transaction, Mr. Blum is shown as beneficially owning 378,108 shares directly and additionally reports indirect beneficial ownership of 2,083 shares held by each of two irrevocable trusts (The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust). The Form 4 was signed by an attorney-in-fact for Mr. Blum.

Insights

Securities Analyst

TL;DR: Insider sale of 5,000 shares is routine given total holdings; transaction appears immaterial to overall ownership.

The reported sale reduces Mr. Blum's direct holdings by 5,000 shares from his prior direct position, leaving 378,108 shares directly owned. The sale price of $48.76 provides a concrete execution price for this small disposition. Indirect holdings via two 2003 irrevocable trusts are each 2,083 shares, noted separately. There are no derivative transactions or option exercises disclosed on this Form 4. Based solely on disclosed amounts, the sale represents a small fraction of total direct beneficial ownership and is unlikely to be material to shareholder control or valuation.

Corporate Governance Expert

TL;DR: Disclosure is clear and complete for a single non-derivative sale; signatures and trust holdings are properly reported.

The filing indicates compliance with Section 16 reporting: the reporting person is identified with title (President & CEO) and relationship checkboxes marked. The transaction code reported is a sale (Code S) with transaction date and price provided. Indirect ownership via named irrevocable trusts is explicitly explained. The Form 4 bears an attorney-in-fact signature, which is acceptable where authorized. No amendments or derivative positions are reported.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blum Robert I

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		S		5,000	D	$48.76	378,108	D
Common Stock								2,083	I	by Trust 1(1)
Common Stock								2,083	I	by Trust 2(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares held by The Bridget Blum 2003 Irrevocable Trust.

2. Shares held by The Brittany Blum 2003 Irrevocable Trust.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Blum	09/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CYTK insider Robert I. Blum report on 09/02/2025?

He reported a sale of 5,000 shares of Cytokinetics common stock on 09/02/2025 at a price of $48.76 per share.

How many CYTK shares does Robert I. Blum beneficially own after the reported sale?

Following the sale, Mr. Blum is reported to beneficially own 378,108 shares directly, plus 2,083 shares in each of two irrevocable trusts.

Does the Form 4 report any option exercises or derivative transactions for CYTK?

No. Table II shows no derivative securities transactions; only a non-derivative sale of common stock is reported.

Who signed the Form 4 for Robert I. Blum?

The Form 4 is signed by John O. Faurescu, attorney-in-fact for Mr. Blum on 09/02/2025.

Are indirect holdings disclosed on the Form 4 for CYTK?

Yes. The filing notes indirect beneficial ownership of 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust.